Heart & Brain Symposium 2018 - Scientific Program

Scientific Program

Preliminary Program

 Thursday, June 28, 2018

15:00 - 15:20
Welcome Address

25%-30% of all ischemic strokes are of cardio-embolic origin where 45% are related to Atrial Fibrillation (AF). Strokes due to AF are devastating ones with high rates of mortality and disability. Therefore, detecting AF, assessing the stroke risk and tailoring the right preventive treatment to an individual patient is extremely important. This session will highlight and discuss all these important issues. 
  • Advances in Detection of AF 
    James ReiffelColumbia University, USA
  • Assessing Stroke Risk in Subjects with AF
    Hooman KamelWeill Cornell Medical Center, USA 
  • Stroke Prevention in AF: The Role of Target-Specific Oral Anticoagulants
    Jonathan HalperinMount Sinai Medical Center, US.

Panel Discussion

16:50 - 17:00Short break

Although AF is the widely discussed issue of cardio-embolic strokes other pathological conditions of the left atrium may be important as a source of embolism. This symposium will shed light on the so far "neglected" topic in cardio-embolic stroke. 
  • Atrial Cardiomyopathy Diagnostic Approaches
    David TirschwellUniversity of Washington Medicine Comprehensive Stroke Center, USA 
  • Fibrotic Atrial Cardiomyopathy 
    Jeffrey Goldberger, University of Miami Hospital, USA 
  • The Role of LAA Occlusion Devices in Stroke Prevention in Patients with AF
    Vivek ReddyDirector of Electrophysiology Laboratories at the Mount Sinai Medical Center, USA 

Panel Discussion

18:25 - 18:30Short break
18:30 - 19:00KEYNOTE LECTURE 
  • Atrial Fibrillation and Stroke: Expanding the Paradigm
    John CammSt George's Hospital Medical School, UK 
19:00Opening Ceremony 
Followed by a Networking Welcome Reception  

Friday, June 29, 2018

09:00 - 09:45

Until recently PFO closure by endovascular procedure was not generally recommended. However, recently the results of 2 RTCs (CLOSE and REDUCE) and the long-term follow-up of the RESPECT trial were published. These results will have an impact on the current practice. The question now is not "should we close"? but "who to close"? This will be the scope of this debate. 
1st Debater: Steven R. Messe, University of Pennsylvania, USA
2nd Debater: Richard Smalling, UTHealth and Memorial Hermann Heart and Vascular Institute, USA 
09:45 - 10:15Coffee Break, Exhibition & Poster Viewing

  • Shadi Yaghi, Brown University, USA 
  • MingMing NingHarvard Medical School, USA
11:45 - 12:30DEBATE SESSION

It is greatly accepted that patients with Embolic Stroke of Unknown Source (ESUS) should go on long-term cardiac monitoring in order to detect sub-clinical AF. However, it is still unknown what is the burden of AF that is clinically relevant to trigger treatment with anticoagulants. This debate will highlight the various opinions: "small vs. extensive" is the dilemma that will be discussed. 
  • The Burden of AF to trigger treatment
    1st Debater: Jeff Healey, McMaster University, Canada
    2nd Debater: Rod Passman, Northwestern Memorial Hospital, USA 
12:30 - 14:00Break, Exhibition & Poster Viewing
14:00 - 14:30KEYNOTE LECTURE
  • Navigate ESUS trial: What did we learn?
    Robert Hart, McMaster University, Canada 
14:30 - 14:35Short break

Cognitive impairment due to vascular pathology of the brain- Vascular Cognitive Impairment (VCI) is an important issue. Understanding the underlying and the related risk factors of VCI as well as the effect of the heart on VCI may have an impact on prevention and treatment of this condition. This symposium will discuss this issue from various aspects. 

  • The Neurovascular Unit and Cognitive Impairment
    Constantino Iadecola, Feil Family Brain and Mind Research Institute, USA
  • Hypertension, Small Vessel Disease and Cognition
    Ralph Sacco, Miller School of Medicine, University of Miami, USA
  • Defining Optimal Brain Health in Adults
    Philip Gorelick, Mercy Health Hauenstein Neuroscience Center, USA 
  • Aortic Stenosis, TAVR and Cognition: Imaging and Clinical Findings
    Ronald Lazar, University of Alabama at Birmingham, USA

Panel Discussion

16:30 - 17:00Coffee Break, Exhibition & Poster Viewing

Stroke due to ESUS imposes difficult clinical dilemma for the treating physician. The magnitude of the problem, practical evaluation and treatment options will be discussed in this symposium. 

  • The Magnitude of the Problem
    Gorgios Tsivgoulis, University of Athens School of Medicine/The University of Tennessee Health Science Center, Greece/USA
  • Evaluation of Patients with ESUS
    Jeffrey Saver, Geffen School of Medicine at UCLA, USA
  • Treatment options
    Gustavo SaposnikUniversity of Toronto, Canada
Panel Discussion

Saturday, June 30, 2018

09:00 - 10:20

There are several practical aspects in the treatment of AF patients with AC. This session will deal with three of these important topics as listed below:
  • How to Improve the Use of Anticoagulation for Stroke Prevention in AF
    Christopher GrangerDuke University School of Medicine, USA 
  • When to Start Anticoagulation after Acute Ischemic Stroke 
    Natan BornsteinShaare Zedek Medical Center, Jerusalem, Israel 
  • Treatment of Acute Stroke in AF Patients with Mechanical Thrombectomy
    Gregory AlbersStanford Stroke Center, USA

    Panel Discussion
10:30 - 11:00Coffee Break, Exhibition & Poster Viewing
11:00 - 11:30KEYNOTE LECTURE
  • Atrial fibrillation and stroke: the first 100 years
Robert HartMcMaster University, Canada 
11:30 - 13:00


  • Kevin Sheth, Yale School of Medicine, USA 
  • Eitan Auriel, Carmel Medical Center, Israel 
13:00 - 14:00
Break, Exhibition & Poster Viewing
14:00 - 15:30


Anticoagulants (AC) are the treatment of choice for stroke prevention in AF patients. However, AC carries a risk of bleeding and especially of Intra-Cerebral Hemorrhage (ICH). Therefore, stroke prevention, acute stroke treatment of AF patients with Mechanical Thrombectomy and when to resume AC after ICH is of a major concern for the treating physician. This symposium will try to clarify these complex and problematic issues. 

  • Stroke Prevention in AF patients at High ICH Risk - Definition and Problems with Medical Management
    Edip GurolHarvard Medical School, USA
  • Reversal Agents
    John EikelboomMcMaster University, Canada
  • Perils of Combination Anticoagulant and Antiplatelet Therapy
    Marc FisherBeth Israel Deaconess Medical Center, Harvard Medical School, USA 
  • Resuming Anticoagulation after ICH
    Larry Goldstein, University of Kentucky, USA

    Panel Discussion


Keep Me Updated